BC
CRSP icon

Bridgefront Capital’s CRISPR Therapeutics CRSP Stock Holding History

Bridgefront Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,832
Closed -$267K – 649
2025
Q1 		$267K Sell
7,832
-9,432
-55% -$400K 0.08% 431
2024
Q4 		$680K Buy
+17,264
New +$815K 0.23% 134
2024
Q3 		– Sell
-4,492
Closed -$243K – 562
2024
Q2 		$243K Buy
+4,492
New +$260K 0.1% 357
2024
Q1 		– Sell
-4,119
Closed -$258K – 405
2023
Q4 		$258K Buy
+4,119
New +$228K 0.19% 213
2023
Q3 		– Sell
-5,387
Closed -$302K – 431
2023
Q2 		$302K Buy
+5,387
New +$306K 0.16% 242

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bridgefront Capital's CRSP Position: Q2 2025 in Review

Bridgefront Capital sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 7,832 shares — an estimated $267K sold.

Bridgefront Capital first reported a position in CRSP in Q2 2023 and held it in 5 quarters. The position peaked at $680K in Q4 2024. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Bridgefront Capital reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bridgefront Capital sold 7,832 CRISPR Therapeutics shares in Q2 2025, an estimated $267K.
  • Bridgefront Capital first reported a position in CRISPR Therapeutics in Q2 2023 and held it in 5 quarters.
  • Bridgefront Capital's CRISPR Therapeutics position peaked at $680K in Q4 2024.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Bridgefront Capital's 13F filing for Q2 2025, filed 14 Aug 2025.